The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia.
elderly
frailty
multiple myeloma
treatment
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
14
04
2022
accepted:
13
02
2023
medline:
25
5
2023
pubmed:
8
3
2023
entrez:
7
3
2023
Statut:
ppublish
Résumé
Multiple myeloma (MM) is a disease of older people, yet factors relating to comorbidity and frailty may threaten treatment tolerability for many of this heterogenous group. There has been increasing interest in defining specific and clinically relevant frailty assessment tools within the MM population, with the goal of using these frailty scores, not just as a prognostic instrument, but also as a predictive tool to allow for a frailty-adapted treatment approach. This paper reviews the various frailty assessment frameworks used in the evaluation of patients with MM, including the International Myeloma Working Group Frailty Index (IMWG-FI), the Mayo Frailty Index and the simplified frailty scale. While the IMWG-FI remains the most widely accepted tool, the simplified frailty scale is the most user-friendly in busy day-to-day clinics based on its ease of use. This paper summarises the recommendations from the Myeloma Scientific Advisory Group (MSAG) of Myeloma Australia, on the use of frailty assessment tools in clinical practice and proposes a frailty-stratified treatment algorithm to aid clinicians in tailoring therapy for this highly heterogeneous patient population.
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
819-824Informations de copyright
© 2023 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.
Références
Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an international myeloma working group report. Blood 2015; 125: 2068-74.
Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122-8.
Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood 2018; 131: 301-10.
Kumar SK, Facon T, Usmani SZ, Plesner T, Orlowski RZ, Touzeau C et al. Updated analysis of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM): the phase 3 Maia study. Blood 2020; 136: 24-6.
McCaughan GJ, Tran S, Durrant S, Harrison SJ, Morton J, Horvath N et al. Trends in outcomes in Australia and New Zealand in autologous stem cell transplantation in older patients with multiple myeloma: an Australasian bone marrow transplant recipient registry study. Blood 2020; 136: 11-2.
Isaacs A, Fiala M, Tuchman S, Wildes TM. A comparison of three different approaches to defining frailty in older patients with multiple myeloma. J Geriatric Oncol 2020; 11: 311-5.
Engelhardt M, Dold SM, Ihorst G, Zober A, Moller M, Reinhardt H et al. Geriatric assessment in multiple myeloma patients: validation of the international myeloma working group (IMWG) score and comparison with other common comorbidity scores. Haematologica 2016; 101: 1110-9.
D'Agostino M, Larocca A, Offidani M, Liberati AM, Gaidano G, Petrucci MT et al. Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. Blood Cancer J 2021; 11: 73.
Milani P, Vincent Rajkumar S, Merlini G, Kumar S, Gertz MA, Palladini G et al. N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. Am J Hematol 2016; 91: 1129-34.
Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia 2020; 34: 224-33.
Stege CAM, van der Holt B, Dinmohamed AG, Sonneveld P, Levin MD, van de Donk N et al. Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities. Leukemia 2020; 34: 1964-6.
Larocca A, Dold SM, Zweegman S, Terpos E, Wäsch R, D'Agostino M et al. Patient-centered practice in elderly myeloma patients: an overview and consensus from the European myeloma network (EMN). Leukemia 2018; 32: 1697-712.
Quach H, Prince HM. Medical Scientific Advisory Group (MSAG) - Clinical Practice Guideline Multiple Myeloma; MSAG Update: Bortezomib, Lenalidomide and Dexamethasone (VRd) for initial treatment of multiple myeloma.Updated March 2017 and July 2020, 3 December 2021.
Bringhen S, D'Agostino M, Paris L, Ballanti S, Pescosta N, Spada S et al. Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. Haematologica 2020; 105: 1937-47.
Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B et al. Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens. J Clin Oncol 2015; 33: 3921-9.
Durie BG, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J 2020; 10: 1-11.
O'Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, Basile FG et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol 2018; 182: 222-30.
Larocca A, Bonello F, Gaidano G, D'Agostino M, Offidani M, Cascavilla N et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood 2021; 137: 3027-36.
Boyle S, Wellard C, Moore EM, Blacklock H, Harrison SJ, Ho PJ et al. Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction. Eur J Haematol 2021; 107: 497-9.
Quach H, Fernyhough L, Henderson R, Corbett G, Baker B, Browett P et al. Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. Br J Haematol 2017; 177: 441-8.